DrugPatentWatch Database Preview
Ironwood Pharms Inc Company Profile
What is the competitive landscape for IRONWOOD PHARMS INC, and when can generic versions of IRONWOOD PHARMS INC drugs launch?
There are eight US patents protecting IRONWOOD PHARMS INC drugs.
There are one hundred and sixty-three patent family members on IRONWOOD PHARMS INC drugs in thirty-eight countries and twelve supplementary protection certificates in ten countries.
Summary for Ironwood Pharms Inc
| International Patents: | 163 |
| US Patents: | 8 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Ironwood Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharms Inc | DUZALLO | allopurinol; lesinurad | TABLET;ORAL | 209203-001 | Aug 18, 2017 | RX | Yes | No | 8,283,369 | ➤ Sign Up | ➤ Sign Up | ||||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | RX | Yes | Yes | 8,084,483 | ➤ Sign Up | ➤ Sign Up | ||||
| Ironwood Pharms Inc | DUZALLO | allopurinol; lesinurad | TABLET;ORAL | 209203-002 | Aug 18, 2017 | RX | Yes | Yes | 8,084,483 | ➤ Sign Up | ➤ Sign Up | ||||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Ironwood Pharms Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,344,012 | Compounds, compositions and methods of using same for modulating uric acid levels | ➤ Sign Up |
| 8,252,828 | S-triazolyl .alpha.-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ➤ Sign Up |
| 8,481,581 | S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ➤ Sign Up |
| 7,435,752 | N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Ironwood Pharms Inc Drugs
Supplementary Protection Certificates for Ironwood Pharms Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016024 | Lithuania | ➤ Sign Up | PRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218 |
| 16/033 | Ireland | ➤ Sign Up | PRODUCT NAME: (I)PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED:-LESINURAD, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/15/1080 20160218 |
| /2016 | Austria | ➤ Sign Up | PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222 |
| C0031 | France | ➤ Sign Up | PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
